NCT04515836 2025-05-06Olaparib in Patients With HRD Malignant MesotheliomaUniversity of ChicagoPhase 2 Recruiting56 enrolled
NCT06217757 2024-05-13Safety and Tolerability of LDRT+Sugemalimab+Chemotherapy+Olaparib for First-Line Treatment of SLFN-11 Positive ES-SCLCSichuan UniversityPhase 1/2 Recruiting45 enrolled